Weight-Loss Injections: Mounjaro Today – and Retatrutide Tomorrow on Harley Street

At CutKilo, we believe in medically supervised, evidence-driven weight-management solutions. In recent years, the landscape of weight-loss injections has shifted dramatically: from older GLP-1 medications to dual-agonists such as Mounjaro, and now to even more ambitious agents such as Retatrutide. If you’ve been researching your options, here’s a deep dive into what these treatments are, how they compare, why you should steer clear of unregulated social-media sales, and why choosing a clinician-led programme (on Harley Street or remote) matters.

The term “weight-loss injections” refers to prescription medications delivered by injection (usually once-weekly) that help regulate appetite, metabolism, and fat storage. They are not miracle pills; they work best when embedded in a broader medical, nutritional and exercise programme.

Key players today include Mounjaro (tirzepatide) – a dual-agonist of GLP-1 and GIP receptors – and coming soon, Retatrutide – a triple-receptor agonist (GLP-1, GIP and glucagon) that has shown even stronger early results.

• Mounjaro is already being prescribed under clinical supervision in the UK for certain patients.
• Retatrutide is still in clinical trials and not yet approved for general use in the UK. Drugs.com
  Because of this evolving science, clinics such as CutKilo are ideally placed to guide patients through safe, responsible use of these medications, and to manage the transition as new drugs become available.

Retatrutide (development code LY-3437943) is a synthetic peptide developed by Eli Lilly and Company designed to act simultaneously on three hormone-receptor pathways:

• GLP-1 (glucagon‐like peptide-1)
• GIP (glucose‐dependent insulinotropic polypeptide)
• Glucagon receptor (GCG) nejm.org
  Put simply: it takes the mechanism of today’s weight-loss injections and adds an extra dimension of hormonal stimulation, with the aim of significantly greater weight-loss outcomes.

In phase 2 trials, Retatrutide delivered impressive results:

• Mean weight reduction of up to ~17.5% at 24 weeks, rising to ~24.2% at 48 weeks in overweight/obese adults. Drugs.com
• A review found participants on the highest dose lost ~22.1% after 48 weeks – surpassing results seen for Mounjaro and other GLP-1 drugs. MedPath
  Such figures have led commentators to call Retatrutide the “next frontier” of weight-loss injections.

Despite the strong early data, Retatrutide is not yet approved for general use. It is currently in late-stage (phase 3) clinical trials. In the UK specifically:

• It is not available outside clinical studies.
• Some sources suggest earliest potential availability in 2026-27 if trials go well and regulatory approval follows.
  In other words: exciting, but not yet here.

Mounjaro (tirzepatide)

• Already licensed for some indications (e.g., type 2 diabetes; in some jurisdictions weight-loss).
• A dual-agonist (GLP-1 + GIP) that has shown impressive weight-loss results when used for medical weight management.
• Strong evidence base; established safety monitoring protocols; your clinician will be familiar with titration, monitoring and integration with nutrition/exercise.

Retatrutide

• Triple-agonist (adds glucagon receptor component) – potentially higher efficacy for weight-loss.
• Trials show very large weight reductions; promising but still investigational.
• Not yet approved, so availability is restricted to clinical studies; long-term safety data still accumulating.

At CutKilo we emphasise the principle: “evidence first, patient safety always.” While it’s tempting to chase “latest and greatest”, responsible weight-loss treatment demands medical oversight, full screening, ongoing monitoring and integration with a holistic weight-management plan.

One of the most urgent issues in the weight-loss injection space is the explosion of unregulated, illicit online sales. This is especially true where high-profile medications (Mounjaro, Retatrutide) gain social-media traction.

What’s happening?

• Reports in the UK highlight that Retatrutide – still in clinical trials – is being offered on Telegram, WhatsApp and via influencers on platforms such as TikTok for “next-gen fat jabs”. The Guardian
• The Medicines and Healthcare products Regulatory Agency (MHRA) has warned that anyone selling Retatrutide for human use is breaking the law. bmj.com

• Unlicensed product: Retatrutide is not licensed for human use in the UK. So any product claiming to be this drug outside authorised trials is almost certainly counterfeit, mis-labelled, dosed incorrectly, or contaminated.
• No safety guarantees: Because the drug is still investigational, long-term effects are still under study. Taking an unregulated version means you bypass the safety monitoring built into clinical programmes.
• Legal consequences: Possessing or administering unlicensed medicines can carry legal and regulatory risks. bmj.com
• Clinical risks: Improper use of potent injections can lead to serious side-effects: hypoglycaemia, gall-bladder issues, pancreatitis, unknown interactions, etc. The bigger the effect the bigger the potential risk.
• False marketing: Social-media ads often make exaggerated claims (“lose 30 kg in 8 weeks” etc.) without reflecting the true context of medical supervision, lifestyle change, eligibility criteria or monitoring.

At CutKilo, we offer a fully supervised Mounjaro weight-loss programme overseen by Dr Emil Gadimali, a UK-registered medical doctor based at 86 Harley Street.

Our approach goes beyond simply prescribing a GLP-1 medication. Every patient receives personalised medical supervision, lifestyle guidance, and progress tracking — ensuring safe, effective, and sustainable results.

Why choose CutKilo over other providers?

Because you’re not just buying a pen — you’re joining a doctor-led programme focused on long-term health improvement, not short-term fixes.

If you’re considering starting Mounjaro for weight loss, choose a service that puts your safety, results, and experience first.
Choose CutKilo – one-way path to better health.

Written by
Dr Emil Gadimali MBBS MBA